NEW YORK, NY / ACCESSWIRE / July 29, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
ProAssurance Corporation (NYSE:PRA)
If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/proassurance-corporation-loss-submission-form?prid=8256&wire=1
Lead Plaintiff Deadline: August 17, 2020
Class Period: April 26, 2019 - May 7, 2020
Allegations against PRA include that: (i) ProAssurance lacked adequate underwriting process and risk management controls necessary to set appropriate loss reserves in its Specialty P&C segment; (ii) ProAssurance failed to properly assess a large national healthcare account that experienced losses far exceeding the assumptions made when the account was underwritten; and (iii) as a result, ProAssurance was subject to materially heightened risk of financial loss and reserve charges.
Enphase Energy, Inc. (NASDAQ:ENPH)
If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/enphase-energy-inc-loss-submission-form?prid=8256&wire=1
Lead Plaintiff Deadline: August 17, 2020
Class Period: February 26, 2019 - June 17, 2020
Allegations against ENPH include that: (1) its revenues, both U.S. and international, were inflated; (2) the Company engaged in improper deferred revenue accounting practices; (3) the Company's reported base points expansion in gross margins were overstated; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
Co-Diagnostics, Inc. (NASDAQ:CODX)
If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/co-diagnostics-inc-loss-submission-form?prid=8256&wire=1
Lead Plaintiff Deadline: August 17, 2020
Class Period: February 25, 2020 - May 15, 2020
According to the filed complaint, Co-Diagnostics and its directors and officers (including PhD-level scientists who should know better) made continual, knowing, and willful misstatements about the Company's main product, a Covid-19 diagnostic test. These misstatements had the effect of pumping up the price of Co-Diagnostics' stock, while Company officers and directors exercised low-priced options and dumped their stock into the market. Co-Diagnostics' fraudulent misstatements displayed a disregard for basic scientific principles and caused investors to lose millions of dollars.
To learn more, contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com:
https://www.accesswire.com/599503/SHAREHOLDER-ALERT-PRA-ENPH-CODX-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines
